With overlapping symptoms, distinguishing possible causes of gastroenteritis can be challenging for any clinician. To further complicate diagnosis, traditional testing methods are slow, labor intensive, and fail to reveal the etiology of a patient’s gastrointestinal symptoms.¹ Fortunately, syndromic testing from the BIOFIRE GI Panel eliminates limitations from conventional methods by providing faster, more accurate, and comprehensive results.

See "Technical Details" tab for full product menu.

A New Option for C. difficile Reporting

A new pouch module option called C. difficile Select* gives users running the BIOFIRE GI Panel on either the BIOFIRE^® FILMARRAY^® TORCH or the BIOFIRE^® FILMARRAY^® 2.0 System the choice to either always report or never report C. difficile results.

*C. difficile Select is available only to customers in the US.

Because traditional stool testing methods are slow and lack sensitivity, clinicians often have to make patient management decisions without a laboratory result. Syndromic testing from the BIOFIRE GI Panel offers fast sample-to-answer turnaround and accurate results, which can:

• Reduce antibiotic use³
• Reduce time to antimicrobial therapy⁴
• Lead to more targeted therapy⁴
• Reduce downstream procedures such as endoscopies and abdominal imaging³

The BIOFIRE GI Panel can streamline workflow by providing faster and more comprehensive test results. Compared to traditional diagnostic methods, syndromic testing from the BIOFIRE GI Panel can:

• Increase diagnostic yield by an average of 31.5%.⁸
• Reduce the number of laboratory tests on average from 3 to 1⁵
• Potentially reduce the number of send-out tests
• Reduce the average time to result by 84%⁵

Guidelines from American College of Gastroenterology and Infectious Disease Society of America:

• Individuals at high risk of spreading disease to others and during known or suspected outbreaks.¹
• Individuals presenting with:^1,7
• Dysentery
• Diarrhea with fever, severe abdominal cramps, or signs of sepsis
• Moderate to severe disease
• Symptoms lasting more than seven days
• Immunocompromised patients with diarrhea

We take a molecular approach to in vitro diagnostic testing. The BIOFIRE GI Panel uses multiplex PCR technology to quickly and accurately identify infectious agents that produce similar symptoms in patients. It’s more sensitive than culture and more efficient than individual and send-out tests.